TRNS vs. EYPT

Last updated Apr 2, 2026

Compare and contrast key facts about Transcat, Inc. (TRNS) and Eyepoint Pharmaceuticals Inc (EYPT).

Performance

TRNS vs. EYPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Transcat, Inc. (TRNS) and Eyepoint Pharmaceuticals Inc (EYPT). The values are adjusted to include any dividend payments, if applicable.

TRNS vs. EYPT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
TRNS Transcat, Inc.	31.34%	-46.35%	-3.28%	54.27%	-23.33%	166.52%	8.85%	67.51%	33.47%	31.94%
EYPT Eyepoint Pharmaceuticals Inc	-28.74%	145.23%	-67.76%	560.29%	-71.41%	86.02%	-57.55%	-17.99%	75.00%	-36.84%

Fundamentals

Market Cap TRNS : $695.10M EYPT : $1.08B
EPS TRNS : $0.97 EYPT : -$3.12
PS Ratio TRNS : 2.17 EYPT : 30.87
PB Ratio TRNS : 2.34 EYPT : 3.53
Total Revenue (TTM) TRNS : $320.40M EYPT : $31.37M
Gross Profit (TTM) TRNS : $103.84M EYPT : $29.31M
EBITDA (TTM) TRNS : $34.58M EYPT : -$239.53M

Returns By Period

In the year-to-date period, TRNS achieves a 31.34% return, which is significantly higher than EYPT's -28.74% return. Over the past 10 years, TRNS has outperformed EYPT with an annualized return of 22.12%, while EYPT has yielded a comparatively lower -7.34% annualized return.

TRNS

• 1D: 1.44%
• 1M: -7.70%
• YTD: 31.34%
• 6M: 3.75%
• 1Y: 0.47%
• 3Y*: -5.89%
• 5Y*: 8.78%
• 10Y*: 22.12%

EYPT

• 1D: 1.01%
• 1M: -29.01%
• YTD: -28.74%
• 6M: 0.81%
• 1Y: 157.82%
• 3Y*: 64.22%
• 5Y*: 3.79%
• 10Y*: -7.34%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TRNS vs. EYPT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TRNS

TRNS Risk / Return Rank: 39
TRNS Sharpe Ratio Rank: 40
TRNS Sortino Ratio Rank: 38
TRNS Omega Ratio Rank: 37
TRNS Calmar Ratio Rank: 40
TRNS Martin Ratio Rank: 40

EYPT

EYPT Risk / Return Rank: 88
EYPT Sharpe Ratio Rank: 91
EYPT Sortino Ratio Rank: 88
EYPT Omega Ratio Rank: 84
EYPT Calmar Ratio Rank: 88
EYPT Martin Ratio Rank: 88

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TRNS vs. EYPT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Transcat, Inc. (TRNS) and Eyepoint Pharmaceuticals Inc (EYPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TRNS	EYPT	Difference
Sharpe ratio Return per unit of total volatility	0.01	2.11	-2.10
Sortino ratio Return per unit of downside risk	0.38	2.75	-2.37
Omega ratio Gain probability vs. loss probability	1.04	1.33	-0.28
Calmar ratio Return relative to maximum drawdown	0.00	3.78	-3.77
Martin ratio Return relative to average drawdown	0.00	9.96	-9.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TRNS vs. EYPT - Sharpe Ratio Comparison

The current TRNS Sharpe Ratio is 0.01, which is lower than the EYPT Sharpe Ratio of 2.11. The chart below compares the historical Sharpe Ratios of TRNS and EYPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TRNS	EYPT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.01	2.11	-2.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.20	0.03	+0.17
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.53	-0.07	+0.60
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	-0.09	+0.25

Correlation

The correlation between TRNS and EYPT is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TRNS vs. EYPT - Dividend Comparison

Neither TRNS nor EYPT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

TRNS vs. EYPT - Drawdown Comparison

The maximum TRNS drawdown since its inception was -93.42%, roughly equal to the maximum EYPT drawdown of -97.73%. Use the drawdown chart below to compare losses from any high point for TRNS and EYPT.

Drawdown Indicators

	TRNS	EYPT	Difference
Max Drawdown Largest peak-to-trough decline	-93.42%	-97.73%	+4.31%
Max Drawdown (1Y) Largest decline over 1 year	-44.83%	-37.14%	-7.69%
Max Drawdown (5Y) Largest decline over 5 years	-63.86%	-87.61%	+23.75%
Max Drawdown (10Y) Largest decline over 10 years	-63.86%	-94.45%	+30.59%
Current Drawdown Current decline from peak	-48.28%	-87.03%	+38.75%
Average Drawdown Average peak-to-trough decline	-35.33%	-76.33%	+41.00%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.78%	14.08%	+9.70%

Volatility

TRNS vs. EYPT - Volatility Comparison

The current volatility for Transcat, Inc. (TRNS) is 12.12%, while Eyepoint Pharmaceuticals Inc (EYPT) has a volatility of 20.37%. This indicates that TRNS experiences smaller price fluctuations and is considered to be less risky than EYPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TRNS	EYPT	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.12%	20.37%	-8.25%
Volatility (6M) Calculated over the trailing 6-month period	34.84%	51.23%	-16.39%
Volatility (1Y) Calculated over the trailing 1-year period	48.01%	75.69%	-27.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	43.20%	118.59%	-75.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	42.17%	100.71%	-58.54%

Financials